Reduction in Odds of Pathological Fracture with Denosumab vs Zoledronic Acid for Bone Metastases
How to Cite
OrthoEvidence. Reduction in Odds of Pathological Fracture with Denosumab vs Zoledronic Acid for Bone Metastases. ACE Report. 2020;9(10):7. Available from: https://myorthoevidence.com/AceReport/Report/12353
Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials.J Am Acad Orthop Surg Glob Res Rev. 2020 Aug; 4(8): e20.00045.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Four studies including 7320 patients with bone metastases from advanced cancer were included in this meta-analysis comparing the likelihood of pathological fracture. Sub-group analyses were performed by tumour origin (endodermal cancer, mesodermal cancer). Pooled results found the likelihood of pathological fracture to be significantly lower in the denosumab group compared to the zoledronic acid g...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE